Bradley S. Galer - 06 Jun 2024 Form 4 Insider Report for Rapport Therapeutics, Inc. (RAPP)

Reporting relationship: Chief Medical Officer
Issuer ticker: RAPP
Reported as of: 06 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2024, 19:44:44 UTC
Prior SEC filing: 09 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Cheryl Gault, Attorney-in-Fact

Key filing fact

Bradley S. Galer filed Form 4 for Rapport Therapeutics, Inc. (RAPP) on 10 Jun 2024.

Key facts

This page summarizes Bradley S. Galer's Form 4 filing for Rapport Therapeutics, Inc. (RAPP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2024, 19:44.

Change

Previous filing in this sequence was filed on 09 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RAPP transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +123,818
Change %
Price: $0.000000
Shares after: 123,818
Date: 06 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 123,818
Exercise price: $17.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares underlying this option shall vest and become exercisable on June 6, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.